RNA
EquityAtrium Therapeutics, Inc. Common Stock
Health Care · Biotechnology
$14.75
+14.75 (+0.00%)
Open
N/A
Day Range
$13.14 - $15.93
52W Range
$13.14 - $73.06
Volume
8M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Insider Activity
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jan 21, 2026 |
HUGHES STEVEN GEORGE Officer |
Sell | 4,895 | $354.6K |
| Jan 21, 2026 |
LEVIN ARTHUR A. Director |
Sell | 1,758 | $127.4K |
| Jan 21, 2026 |
FLANAGAN WILLIAM MICHAEL Officer |
Sell | 6,534 | $473.4K |
| Jan 21, 2026 |
MACLEAN MICHAEL F. Chief Financial Officer |
Sell | 4,542 | $329.1K |
| Jan 21, 2026 |
MCCARTHY TERESA Officer |
Sell | 2,929 | $212.2K |
| Jan 21, 2026 |
BOYCE SARAH Chief Executive Officer |
Sell | 14,387 | $1.0M |
| Jan 7, 2026 |
HUGHES STEVEN GEORGE Officer |
Sell | 2,373 | $171.4K |
| Jan 7, 2026 |
BOYCE SARAH Chief Executive Officer |
Sell | 8,576 | $619.4K |
| Jan 7, 2026 |
MORIARTY JOHN B Officer |
Sell | 2,374 | $171.5K |
| Jan 7, 2026 |
MACLEAN MICHAEL F. Chief Financial Officer |
Sell | 1,974 | $142.6K |
Institutional Ownership
| Holder | Shares | % Held | Value |
|---|---|---|---|
| Vanguard Group Inc | 13,649,250 | 8.80% | $201.3M |
| Blackrock Inc. | 12,850,801 | 8.28% | $189.5M |
| RA Capital Management, L.P. | 8,641,031 | 5.57% | $127.5M |
| Janus Henderson Group PLC | 6,939,503 | 4.47% | $102.4M |
| Balyasny Asset Management LP | 6,040,590 | 3.89% | $89.1M |
| Pentwater Capital Management Lp | 6,026,500 | 3.88% | $88.9M |
| Avoro Capital Advisors LLC | 5,455,000 | 3.52% | $80.5M |
| HBK Investments L P | 4,365,000 | 2.81% | $64.4M |
| State Street Corporation | 4,097,885 | 2.64% | $60.4M |
| Goldman Sachs Group Inc | 3,776,785 | 2.43% | $55.7M |
Latest News
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Delays Stockholder Meeting Ahead of Spin-Off, Novartis Merger
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivery of RNA therapeutics to the heart to transform the care for people living with cardiomyopathies. The company was formerly known as Bryce Therapeutics, Inc. Bryce Therapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California.
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for RNA
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for RNA.